Association between early parenteral nutrition and the development of bronchopulmonary dysplasia in preterm infants / 中国当代儿科杂志

OBJECTIVES@#To study the relationship between early parenteral nutrient intake and the development of bronchopulmonary dysplasia (BPD) in preterm infants with gestational age less than 32 weeks who could not receive enteral nutrition within one week after birth.@*METHODS@#A retrospective study was conducted on preterm infants born between October 2017 and August 2022 with gestational age less than 32 weeks who were admitted to the Neonatal Intensive Care Unit in Children's Hospital of Soochow University within 24 hours after birth and relied solely on parenteral nutrition within the first week of life. The study population included 79 infants with BPD and 73 infants without BPD. Clinical data during hospitalization were compared between the two groups.@*RESULTS@#The proportions of infants with weight loss of more than 10% after birth, extrauterine growth retardation, and parenteral nutrition-associated cholestasis in the BPD group were higher than in the non-BPD group (P<0.05). The time to regain birth weight, time to achieve full enteral feeding, and corrected gestational age at discharge were longer in the BPD group than in the non-BPD group. The Z-scores of physical growth at corrected gestational age of 36 weeks were lower in the BPD group than in the non-BPD group (P<0.05). The BPD group had a higher fluid intake and a lower calories intake in the first week than the non-BPD group (P<0.05). The starting dose and total amount of amino acids, glucose, and lipids in the first week were lower in the BPD group than in the non-BPD group (P<0.05). The BPD group had a higher glucose-to-lipid ratio on the third day and higher energy-to-nitrogen and glucose-to-lipid ratios on the seventh day after birth than the non-BPD group (P<0.05).@*CONCLUSIONS@#Preterm infants with BPD had lower intake of amino acids and lipids and a lower proportion of calories provided by amino acids and lipids in the first week of life, which suggests an association between early parenteral nutrition intake and the development of BPD.

Caracterización de la displasia broncopulmonar según dos definiciones en prematuros chilenos / Characterization of bronchopulmonary dysplasia in relation with two definitions in chilean preterm infants

Existen controversias en la definición de la displasia broncopulmonar, siendo las más utilizadas el requerimiento de O2 durante 28 días o a las 36 semanas de edad gestacional corregida (EGC). Nuestro objetivo fue determinar la incidencia y características clínicas de los prematuros nacidos antes de las 32 semanas (RNP≤ 32s) con requerimiento de O2 a los 28 días de vida (DBP28d) y a las 36 semanas de EGC (DBP36s) en una unidad neonatal de Santiago, Chile, entre los años 2012 y 2019. Es un estudio descriptivo, retrospectivo con componente analítico. La población estudiada incluyó 535 RNP≤ 32s, vivos a las 36 semanas o dados de alta después de las 34 semanas de EGC. De los 242 prematuros DBP28d, 203 (83,88%) fueron DBP36s; 16 de los 242 (6%) requirió O2 durante menos de 28 días consecutivos, de los cuales 7, aún lo requerían a las 36 semanas. Los predictores de DBP36s fueron: sexo masculino (OR 2,42, IC del 95%: 1,24-4,69), peso al nacer (OR 1, IC del 95%: 0,99-1), edad gestacional (OR 0,75, IC del 95%: 0,57-0,97), APGAR a los 5 min, (OR 0,01, IC del 95%: 0,003-0,05), el requerimiento de presión positiva continua o cánula nasal de alto flujo (OR 1,1, IC del 95%: 1,04-1,17) y días de ventilación mecánica invasiva (OR 1,1,95% IC: 1-1,2). Conclusiones: No encontramos una diferencia significativa en la incidencia de DBP entre las definiciones de DBP28d y DBP36s; y la mayoría de los RNP< 32s con diagnóstico de DBP36s se pudieron identificar a los 28 días de vida.

Bronchopulmonary dysplasia (BPD) is the most common chronic lung disease in premature newborns. It is commonly defined as a need for supplemental O2 for 28 days or at 36 weeks postmenstrual age (PMA) (BPD36w). Our objective was to determine the incidence and clinical characteristics of premature neonates born at less than 32 weeks (PNB< 32w) with O2 requirement at 28 days of life (DBP28d) and DBP36w in a neonatal unit of Santiago, Chile, between 2012 and 2019. This is a descriptive, retrospective study with an analytical component. The study population included 535 PNB< 32w, alive at 36 weeks or discharged after 34 PMA. Of the 242 premature BPD28d, 203 (83,88%) were BPD36w; 16 (6%) required O2 for less than 28 consecutive days, of which 7 still required it at 36 weeks. The predictors of BPD36w were: male (OR 2.42, 95% CI: 1.24-4.69), birth weight (OR 1, 95% CI: 0.99-1), gestational age (OR 0.75, 95% CI: 0.57-0.97), APGAR at 5 min, (OR 0.01, 95% CI: 0.003-0.05), continuous positive pressure or high-flow nasal cannula requirement (OR 1.1, 95% CI: 1.04-1.17) and days of invasive mechanical ventilation (OR 1.1, 95% CI: 1-1.2). Conclusions: We did not find a significant difference in the incidence of BPD between the definitions of BPD28d and BPD36s; and the majority of PNB < 32w diagnosed with BPD36w can be identified at 28 days of life.

Tratamento da broncodisplasia pulmonar: uma revisão sistemática / Treatment of pulmonary broncodysplasia: a systematic review

Introdução: Displasia broncopulmonar (DBP) é uma grave complicação entre pré-termos, com incidência inversamente proporcional à idade gestacional. Resulta de processo inflamatório com desenvolvimento pulmonar anormal, gerando graves consequências. Apesar de serem limitadas e não afetarem substancialmente a evolução da doença, as opções terapêuticas para prevenção e tratamento da DBP são importantes, porém carecem de melhor elucidação. Objetivos: Abordar aspectos recentes da literatura quanto à prevenção e tratamento da DBP. Métodos: Revisão de literatura na base de dados MEDLINE, em 2021, incluindo ensaios clínicos controlados e randomizados, realizados em humanos e nos últimos 5 anos, excluindo estudos não diretamente relacionados ao tema. Resultados: A incidência de DBP foi menor naqueles casos leves expostos à budesonida inalatória, óleo de peixe intravenoso contendo emulsão lipídica (OP) e ácido docosahexaenoico (DHA). Houve aumento da sobrevida com uso de hidrocortisona em baixas doses, dexametasona com redução gradual da dose, por 42 dias, e dexametasona associada a corticosteroides pós-natais (este ainda com redução dos prejuízos no neurodesenvolvimento). Hidrocortisona, dexametasona, dipropianato de hidrofluoalcano-beclometasona inalado e OP reduziram o tempo ou a necessidade de ventilação e oxigenoterapia. A mortalidade foi menor nos estudos envolvendo hidrocortisona e elevada no que avaliou budesonida. As principais complicações foram sepse, retinopatia, hemorragia intraventricular e enterocolite necrosante, nos estudos abordando DHA, hidrocortisona, dexametasona e óxido nítrico inalado. Conclusão: Abordagens terapêuticas satisfatórias foram os glicocorticoides associado à terapia ventilatória e à abordagem precoce. Não houve benefícios com uso de ventilação com insuflações sustentadas, administração de dipropionato de hidrofluoralcano-beclometasona inalada e DHA.

Introduction: Bronchopulmonary dysplasia (BPD) is a complication among preterms, with an incidence inversely proportional to gestational age. It results from an inflammatory process that causes abnormal lung development, with severe consequences. Although therapeutic options are limited and do not substantially strike the course of the disease, they are important tools and need further elucidation. Purpose: Address the most recent aspects of the literature regarding the prevention and treatment of BPD. Methods: A literature review was carried out in the MEDLINE database, in 2021, in which only controlled and randomized clinical studies performed in humans in the last 5 years were included. Studies that were not directly related to the theme were excluded. Results: The incidence of BPD was lower in those cases exposed to inhaled budesonide, intravenous fish oil containing lipid emulsion (FO) and docosahexaenoic acid (DHA). There was improvement in survival with a lowdose use of hydrocortisone, dexamethasone with gradual dose reduction, and dexamethasone associated with postnatal corticosteroids (which generated reduction in neurodevelopmental impairments as well). Hydrocortisone, dexamethasone, inhaled hydrofluoalkane-beclomethasone dipropynate and FO reduced the time or need for ventilation and oxygen therapy. The main complications were sepsis, retinopathy, intraventricular hemorrhage and necrotizing enterocolitis in studies that addressed DHA, hydrocortisone, dexamethasone and inhaled nitric oxide. Conclusion: The therapeutic approaches that proved to be conclusive were the use of glucocorticoids associated with ventilatory therapy and an early approach. No benefits were found with the use of ventilation with sustained inflation, administration of inhaled hydrofluoralkane-beclomethasone dipropionate and DHA.

Expert consensus on the follow-up management of bronchopulmonary dysplasia in preterm infants after discharge / 中国当代儿科杂志

Bronchopulmonary dysplasia (BPD) is a common chronic lung disease in preterm infants and seriously affects the quality of life of preterm infants. BPD is a life-threatening disease to preterm infants and may lead to serious sequelae including feeding difficulties, recurrent lower respiratory tract infection, airway hyperreactive diseases, growth retardation, and neurodevelopmental delay. In order to further standardize the follow-up management of preterm infants with BPD after discharge, based on related clinical evidence in China and overseas and practice experience, the Neonatal Evidence-Based Medicine Group, Committee of Neonatal Medicine, Cross-Strait Medical and Health Exchange Association, formulated this expert consensus from the aspects of the follow-up and management of respiratory diseases, growth and development, pulmonary hypertension, nerve dysplasia, metabolic bone disease, and vaccination of preterm infants with BPD after discharge.

El rol de la hipertensión pulmonar en la displasia broncopulmonar / The role of pulmonary hypertension on bronchopulmonary dysplasia

Resumen Hace 50 años Northway describió la Displasia Broncopulmonar (DBP), en nacidos de pretérmino expuestos a ventilación mecánica. Desde entonces, ha aumentado la sobrevida de ellos; sin embar go, ha aparecido una "nueva DBP" y la incidencia de esta no ha disminuido. Una de las caracte rísticas de esta patología es la remodelación vascular anómala, que en su expresión más severa se conoce como Hipertensión Pulmonar (HP); con una incidencia de 17%, que es proporcional a la severidad de la DBP (33% en DBP severa); y como un factor de mortalidad (hasta un 48% mortali dad a 2 años con HP por DBP). Debido a esto resulta importante conocer los métodos diagnósticos y alternativas terapéuticas, tema que se discute en esta revisión. Considerando la alta mortalidad de la asociación HP-DBP, adquiere importancia una estrategia de tamizaje en la población de riesgo. El gold standard para el diagnóstico de HP es el cateterismo cardíaco, sin embargo, el ecocardio-grama transtorácico es una herramienta útil para el tamizaje y diagnóstico de HP en pacientes dis-plásicos, con mediciones cuantitativas y cambios cualitativos en la evaluación diagnóstica. A nivel sanguíneo el péptido natriurético tipo B (BNP), ha mostrado ser útil en el seguimiento; en cuanto a imágenes, la tomografía computarizada se utiliza en casos severos. En cuanto a las terapias, se han propuesto el óxido nítrico inhalado como vasodilatador pulmonar, los inhibidores de la fosfodies-terasas -sildenafil-, los antagonistas de la endotelina -bosentán- y los análogos de prostaciclinas -iloprost-. Aún no se cuenta con evidencia de alta calidad para su uso, dosis y duración del trata miento, pero hay variadas experiencias clínicas. Además, es relevante el cuidado interdisciplinario, destacando optimizar la nutrición. El desafío es lograr una prevención efectiva de la DBP y de sus complicaciones. Un protocolo de tamizaje de HP debe asociarse a una estratificación de riesgo y directrices de tratamiento.

Abstract 50 years ago, Northway described Broncopulmonary Dysplasia (BPD) in preterm infants exposed to mechanical ventilation. Since then, their survival has increased, nevertheless a "new BPD" has appeared and its incidence has not diminished. One of the characteristics of this pathology is the the abnormal vascular remodeling, which in its most severe expression is known as Pulmonary Hyper tension (PH); with an incidence of 17% in patients with BPD, which is proportional to the severity of the disease (33% in severe BPD), and as mortality factor (up to 48% 2-year mortality in PH-BPD). Thereby, it is important to know the diagnostic methods and therapeutic alternatives, topics discus sed in this review. Considering the high mortality in BPD associated PH, screening strategies in at risk population become important. The gold standard is cardiac catheterization; however, transtho-rathic echocardiography is a useful tool for the screening and diagnosis of PH in displasic patients, using cuantitive measures and cualitative changes in the evaluation. Seric type-B natriuretic peptide has shown to be useful for follow-up; regarding images, CT scan is used in severe cases. In terms of therapy; inhaled Nitric Oxide as a pulmonary vasodilator, phosphodiesterase inhibitors -sildenafil-, endotelin antagonists -bosentan-, and prostacyclin analogues -iloprost-, have been proposed. Their use, dosis and treatment lenght still lack support of high quality evidence, but diverse clinical expe riences have been described. Interdisciplinary care is also important, highlighting to optimize nu trition. Therefore, the challenge is to effectively prevent BPD and its complications. A PH screening protocol should be associated with risk stratification and treatment guidelines.

Less invasive beractant administration in preterm infants: a pilot study

OBJECTIVES: The aims of this study were to assess the efficacy and feasibility of a new, less invasive surfactant administration technique for beractant replacement using a specifically designed cannula in preterm infants born at <32 weeks of gestation and to compare short- and long-term outcomes between this approach and standard treatment, consisting of intubation, administration of surfactant and early extubation to nasal continuous positive airway pressure. METHOD: This was a single-center, prospective, open-label, non-randomized, controlled pilot study with an experimental cohort of 30 patients treated with less invasive surfactant administration and a retrospective control group comprising the 30 patients most recently treated with the standard approach. Beractant (4 ml/kg) was administered as an exogenous surfactant in both groups if patients on nasal continuous positive airway pressure during the first three days of life were in need of more than 30% FiO2. Clinicaltrials.gov: NCT02611284. RESULTS: In the group with less invasive surfactant administration, beractant was successfully administered in all patients. Thirteen patients (43.3%) in the group with less invasive surfactant administration required invasive mechanical ventilation for more than 1 hour during the first 3 days of life, compared with 22 (73%) in the control group (p<0.036). The rate of requiring invasive mechanical ventilation for more than 48 hours was similar between the infants in the two groups (46% vs. 40%, respectively). There were no differences in other outcomes. CONCLUSION: The administration of beractant (4 ml/kg) using a less invasive surfactant administration technique with a specifically designed cannula for administration is feasible. Moreover, early invasive mechanical ventilation exposure is significantly reduced by this method compared with the strategy involving intubation, surfactant administration and early extubation.

La nueva displasia broncopulmonar desde el punto de vista de neumólogo pediatra / New bronchopulmonary dysplasia, from a pediatric pulmonologist´s perspective

Bronchopulmonary dysplasia (BPD) is the most prevalent chronic lung disease of prematurity. The so-called new BPD has replaced the classic BPD described by Northway, as a result of maternal use of corticosteroids, early surfactant and less aggressive mechanical ventilation and the survival of younger premature, born during the canalicular stage and that completed their alveolization outside the uterus. The new BPD is a less severe disease, but lung function is impaired in the long-term. An update of the new BPD, focused on the management after discharge from neonatology, from a pediatric pulmonologist perspective is presented.

La Displasia Broncopulmonar (DBP) es la enfermedad pulmonar crónica más prevalente del prematuro. La denominada nueva DBP ha reemplazado a la DBP clásica descripta por Northway, como consecuencia del uso de corticoides maternos, surfactante precoz, ventilación mecánica menos agresiva y la sobrevivencia de prematuros más pequeños, que nacen en etapa canalicular de su desarrollo pulmonar y completan su alveolización fuera del útero. La nueva DBP es una patología menos severa, pero con compromiso funcional respiratorio a largo plazo. A continuación se describe una actualización de la nueva DBP, enfocada en el manejo realizado luego del alta de neonatología, desde el punto de vista del Neumólogo Pediatra.

Stem Cell Therapy for Bronchopulmonary Dysplasia: Bench to Bedside Translation

Bronchopulmonary dysplasia (BPD), a chronic lung disease affecting very premature infants, is a major cause of mortality and long-term morbidities despite of current progress in neonatal intensive care medicine. Though there has not been any effective treatment or preventive strategy for BPD, recent stem cell research seems to support the assumption that stem cell therapy could be a promising and novel therapeutic modality for attenuating BPD severity. This review summarizes the recent advances in stem cell research for treating BPD. In particular, we focused on the preclinical data about stem cell transplantation to improve the lung injury using animal models of neonatal BPD. These translational research provided the data related with the safety issue, optimal type of stem cells, optimal timing, route, and dose of cell transplantation, and potency marker of cells as a therapeutic agent. Those are essential subjects for the approval and clinical translation. In addition, the successful phase I clinical trial results of stem cell therapies for BPD are also discussed.

Effects of therapeutic approach on the neonatal evolution of very low birth weight infants with patent ductus arteriosus / Efeitos da abordagem terapêutica da persistência de canal arterial sobre a evolução neonatal de recém-nascidos de extremo baixo peso

OBJECTIVE: To analyze the effects of treatment approach on the outcomes of newborns (birth weight [BW] < 1,000 g) with patent ductus arteriosus (PDA), from the Brazilian Neonatal Research Network (BNRN) on: death, bronchopulmonary dysplasia (BPD), severe intraventricular hemorrhage (IVH III/IV), retinopathy of prematurity requiring surgical (ROPsur), necrotizing enterocolitis requiring surgery (NECsur), and death/BPD. METHODS: This was a multicentric cohort study, retrospective data collection, including newborns (BW < 1000 g) with gestational age (GA) < 33 weeks and echocardiographic diagnosis of PDA, from 16 neonatal units of the BNRN from January 1, 2010 to Dec 31, 2011. Newborns who died or were transferred until the third day of life, and those with presence of congenital malformation or infection were excluded. Groups: G1 - conservative approach (without treatment), G2 - pharmacologic (indomethacin or ibuprofen), G3 - surgical ligation (independent of previous treatment). Factors analyzed: antenatal corticosteroid, cesarean section, BW, GA, 5 min. Apgar score < 4, male gender, Score for Neonatal Acute Physiology Perinatal Extension (SNAPPE II), respiratory distress syndrome (RDS), late sepsis (LS), mechanical ventilation (MV), surfactant (< 2 h of life), and time of MV. Outcomes: death, O2 dependence at 36 weeks (BPD36wks), IVH III/IV, ROPsur, NECsur, and death/BPD36wks. Statistics: Student's t-test, chi-squared test, or Fisher's exact test; Odds ratio (95% CI); logistic binary regression and backward stepwise multiple regression. Software: MedCalc (Medical Calculator) software, version 12.1.4.0. p-values < 0.05 were considered statistically significant. RESULTS: 1,097 newborns were selected and 494 newborns were included: G1 - 187 (37.8%), G2 - 205 (41.5%), and G3 - 102 (20.6%). The highest mortality was observed in G1 (51.3%) and the lowest in G3 (14.7%). The highest frequencies of BPD36wks (70.6%) ...

OBJETIVO: Analisar os efeitos da terapêutica adotada para o canal arterial (CA) em recém-nascidos (RN) < 1.000gadmitidos em unidades neonatais (UN) da Rede Brasileira de Pesquisas Neonatais (RBPN), sobre os desfechos: óbito, displasia broncopulmonar (DBP), hemorragia intraventricular grave (HIVIII/IV), retinopatia da prematuridade cirúrgica (ROPcir), enterocolite necrosante cirúrgica (ECNcir) e o desfecho combinado óbito e DBP. MÉTODOS: Estudo multicêntrico, de coorte, coleta de dados retrospectiva, incluindo RN de 16 UN da RBPN de 01/01/2010 a 31/12/2011, PN < 1.000 g, idade gestacional (IG) < 33 semanas e diagnóstico ecocardiográfico de PCA. Excluídos: óbitos ou transferências até o terceiro dia de vida, infecções congênitas ou malformações. Grupos:G1 - conservadora (sem intervenção medicamentosa ou cirúrgica), G2 - farmacológica (indometacina ou ibuprofeno) e G3 - cirúrgico (com ou sem tratamento farmacológico anterior). Analisou-se: uso de esteroide antenatal, parto cesárea, PN, IG, Apgar5' < 4, sexo masculino, SNAPPE II, síndrome do dDesconforto respiratório (SDR), sepse tardia, ventilação mecânica (VM), surfactante < 2 horas de vida, tempo de VM e os desfechos: óbito, dependência de oxigênio com 36 semanas (DBP36s), HIV III/IV, ROPcir, ECNcir e óbito/DBP36s. Estatística: Teste t-Student, Qui-Quadrado ou teste Exato de Fisher. Testes de Regressão Binária Logística e Regressão Múltipla Stepwise Backward. MedCalc (Medical Calculator) software, versão 12.1.4.0.p < 0,05. RESULTADOS: Foram selecionados 1.097 RN e 494 foram incluídos: G1-187 (37,8%), G2-205 (41,5%) e G3-102 (20,6%). Verificou-se: maior mortalidade (51,3%) no G1 e menor no G3(14,7%); maior frequência DBP36s (70,6%) e ROPcir (23,5%) ...

Saberes e práticas das mães sobre o uso de broncodilatador em crianças com displasia broncopulmonar no domicílio: subsídios para a enfermagem pediátrica / Knowledge and practices of mothers of bronchodilator use in children with bronchopulmonary dysplasia at home: subsidies for pediatric nursing

Esta pesquisa teve como objeto de estudo os saberes e práticas das mães sobre o uso de broncodilatador em crianças com displasia broncopulmonar, e como objetivos: desvelar os saberes e práticas das mães sobre o uso de broncodilatador em seus filhos com displasia broncopulmonar no domicílio; conhecer os cuidados realizados pelas mães no uso do broncodilatador em seu filho com displasia broncopulmonar no domicílio e descrever as reações percebidas pelas mães em seus filhos após o uso da medicação. Trata-se de um estudo descritivo com abordagem qualitativa. O cenário foi um ambulatório de pneumologia localizado no Município do Rio de Janeiro e os sujeitos, 14 mães de crianças portadoras de displasia broncopulmonar, com idades entre 0 e 2 anos. A coleta dos dados foi realizada através da entrevista semiestruturada, no mês de julho de 2014. Utilizada a análise de conteúdo de Bardin. Como resultados, emergiram duas categorias: os saberes e medos das mães sobre o uso do broncodilatador eas práticas de cuidado da mãe na administração do broncodilatador na criança. A primeira categoria compreende quatro subcategorias: conhecimento das mães sobre a ação do medicamento; sinais de alerta percebidos pelas mães para o uso do medicamento na criança; os efeitos percebidos pelas mães após o uso do medicamento na criança e os medos relacionados ao uso do broncodilatador. A segunda categoria abrange três subcategorias: cuidados com o posicionamento da criança; cuidados com a higiene da criança e cuidados com o espaçador. A maioria das mães consegue identificar a partir dos seus saberes e de seu universo vocabular as principais ações dos broncodilatadores, no entanto podem-se evidenciar alguns relatos com informações inconsistentes, o que nos faz supor a ausência de orientações por parte dos profissionais junto a essa clientela. O esforço respiratório configura-se como sinal de alerta para que as mães utilizem a medicação para tentar evitar a crise respiratória...

This research studied the knowledge and practices of mothers on the use of bronchodilators in children with bronchopulmonary dysplasia, and had the following objectives: to reveal the knowledge and practices of mothers of bronchodilator use in their children with bronchopulmonary dysplasia at home; to understand the care provided by mothers in bronchodilator use in your child with bronchopulmonary dysplasia at home and to describe the reactions perceived by mothers in their children after using the medication. This is a descriptive qualitative study. The scenario was a pulmonology clinic located in the city of Rio de Janeiro and had as subjects, 14 mothers of children with bronchopulmonary dysplasia, aged between 0 and 2 years old. Data collection was conducted through a semi-structured interview on July 2014. It was used Bardin's content analysis. As a result, two categories emerged: the mothers' knowledge and fears about the bronchodilator use and the mothers' care practices in the bronchodilator administration on their children. The first category comprises four subcategories: the mothers' knowledge of the action of the drug; the warning signs perceived by mothers leading to the use of the drug in their children; the effects noticed by the mothers after the use of the medicine in their children and the fears related to the use of bronchodilators. The second category includes three subcategories: the positioning of the child; the child hygiene and the care of the spacer. Most mothers were able to explain based on their knowledge and using their own words, the main actions of bronchodilators. However, there were some inconsistent information, which makes us realize the absence of a clear guidance from the professionals and this clientele. The respiratory effort appears as a warning sign for mothers leading to the use of the drug intending to prevent a respiratory crisis...

Displasia Broncopulmonar / Bronchopulmonary Dysplasia

Os avanços na sobrevivência de bebês cada vez mais prematuros aumentaram o número de casos de displasia bronco-pulmonar. Após cerca de 40 anos de sua descrição inicial, muitos conceitos foram modificados sobre a doença, evoluindo dos estágios clássicos descritos inicialmente para um agravo diretamente relacionado à inibição do desenvolvimento pulmonar. Esta revisão descreve as principais evidências relacionadas aos mecanismos fisiopatológicos e às intervenções disponíveis no acompanhamento dos pacientes com a doença instalada. Os fatores que contribuem para a patogênese da doença são conhecidos. Entretanto, recentes estudos têm demonstrado como esses fatores interferem no crescimento e no remodelamento pulmonar, além da existência de uma possível base genética, sinalizando a suscetibilidade individual no desenvolvimento de formas severas de doença. O manuseio da displasia broncopulmonar consiste em minimizar a agressão pulmonar, reduzir a inflamação e facilitar o crescimento pulmonar. Estratégias atuais e futuras para otimizar a evolução alongo prazo nesses bebês dependem da integração de pesquisasnos campos de melhor conhecimento dos mecanismos de resposta ao dano pulmonar e na redução da gravidade das sequelas cardiopulmonares.

The improved survival of extremely premature infants has contributed to an increase in the number of infants who develop bronchopulmonary dysplasia (BDP). Nearly 40 years after its original description, BDP has evolved, from the classical stages initially described to a disease characterized largely by impaired lung development. This review describes the mechanisms that contribute to the pathogenesis of BDP as well as current therapies for its treatment. The factors that contribute to the pathogenesis of BDP have been well described. However, recent studies have better defined how these factors modulate lung growth, as well as the possibility of a genetic basis, indicating that there is individual susceptibility to the more severe forms of the disease. Treatment of BDP is aimed at minimizing lung injury, reducing inflammation, and facilitating lung growth. Current and future strategies that improve long-term outcomes in infants with BDP will depend on successful integration ofbasic research on the fundamental mechanisms of lung development and response to injury. There is a need for studies ofnovel interventions to reduce the incidence and severity of the cardiopulmonary sequelae of BDP.

Curso clínico y pronóstico a un año de una cohorte de prematuros dados de alta con oxígeno domiciliario en Bogotá, Colombia / The clinical course and one year forcast for a cohort of premature infants who were discharged with home oxygen in Bogota, Colombia

Objetivo Documentar el curso clínico y pronóstico de una cohorte de niños prematuros dados de alta con oxígeno domiciliario en Bogotá, Colombia. Método Cohorte prospectiva de 194 prematuros de 34 o menos semanas de edad gestacional (EG) al nacer, egresados de 12 unidades neonatales con oxígeno suplementario, seguidos hasta la edad corregida de 12 meses para determinar supervivencia, crecimiento, desarrollo y morbilidad. Resultados 49 niños (25,3 %) tenían una oxigenodependencia leve y 145 (74,7 %) moderada-severa. Se presentaron 3 muertes (1,5 %), el estado vital a 40 semanas de EG fue conocido en 169 pacientes (87,1 %) y en 103 (53 %) a 12 meses. La lactancia materna fue exitosa en 147 (75,8 %) niños a 40 semanas. La antropometría al año fue: peso 8 991 g, talla 73 cm y perimetro craneano 46,2 cm. A las 40 semanas y a 3 meses 74,1 % y 22,7 % de la cohorte aún utilizaba oxígeno el cual fue descontinuado en promedio a los109 días postnatales. El 56,8 % de los niños tuvo al menos un reingreso y 47 % por patologías respiratorias. Sólo se tamizó para retinopatía al 71 % y en ellos la incidencia de retinopatía de la prematurez (ROP) fue 38 % con 3 cirugías y 1 niño ciego. Un tamizado neuropsicomotor y sensorial se realizó solamente en 19 % encontrando algún tipo de alteración neuropsicomotriz en 30 %, refractiva en 40 % y auditiva en 5 %. Conclusión Más del 60 % de los niños oxígeno-dependientes fueron dados de alta sin plan de seguimiento estructurado. El problema de los niños oxigenodependientes es complejo y nuestros datos sugieren un gran espacio para mejorar el seguimiento.

Objective Documenting the clinical course and forecast for a concurrent cohort of discharged preterm infants who received home oxygen in Bogota,Colombia. Methods This was a prospective study of a concurrent cohort of 194 newborn infants having 34 weeks gestational age (GA) or less at birth who were born in 12 institutions and followed up for one year of corrected age to assess mortality, morbidity, growth and development. Results Oxygen dependency was mild in 49 infants (25.3 %) and moderate-severe in 145 of them (74.7 %). There were 3 deaths; vital status was known in 169 infants at 40 weeks GA (87.1 %) and 103 (53%) at 1 year. Breast feeding at term was successful in 147 (75.8 %) infants. Growth indices at one year were appropriate (8,991 g weight, 73 cm height and 46.2 cm head circumference) 74.1 % of the cohort were still receiving home oxygen at 40 weeks and and 22.7 % at 3 months and oxygen was discontinued on average on postnatal day 109. 56.8 % of the cohort were readmitted to hospital at least once, 47% of them because of respiratory conditions. Only 71 % had ophthalmological screening and retinopathy of prematurity (ROP) was detected in 38 % of cases (4 severe cases: 3 laser surgery and 1 blind infant). Neuro-psychomotor and sensorial screening tests were only performed on 19 % of the infanys. Conclusion More than 60 % of newborn infants discharged with home oxygen lacked structured follow-up. Oxygen-dependancy in infants is complex; our data suggested that there is plenty of room for improvement in Bogotá in that respect.

Impacto de la inmunoprofilaxis en una población de lactantes prematuros con y sin displasia broncopulmonar / Impact of immunoprophylaxis in a population of preterm infants with and without bronchopulmonary dysplasia

Con el fin de objetivar el impacto de la infección por Virus Sincicial Respiratorio (VSR) se analizó una cohorte de prematuros (PT) atendidos en nuestro consultorio de seguimiento de alto riesgo (CSAR) entre los años 1998 y 2004. A par tir del año 2006 el Hospital incorpora el anticuerpo monoclonal Palivizumab (PVZ) para la profilaxis de VSR en esta población vulnerable. Objetivo: analizar el impacto de la profilaxis con PVZ en la población de lactantes PT con y sin displasia broncopulmonar (DBP). Población: PT atendidos en el CSAR del Hospital Garrahan entre los años 1998- 2004 y 2006-2010. Diseño y Método: estudio longitudinal y observacional mediante comparación de riesgo de hospitalización por VSR entre la cohor te retrospectiva que no recibió PVZ (SP) vs una cohor te prospectiva que recibió profilaxis (CP) Resultados: SP: 154 pacientes, CP: 99 pacientes. La tasa de internación en el grupo SP fue 26% (21% en el grupo sin DBP y 28% para el grupo con DBP); la tasa de internación en el grupo CP disminuyó a 6% (5% y 6,3% para los PT sin y con DBP). Estas diferencias resultaron significativas (RR 0,22 IC95% 0,10 a 0,51); el NNT (número necesario a tratar) fue de 5. Conclusiones: la incorporación de inmunoprofilaxis en este grupo de riesgo produjo un impor tante descenso de la tasa de internación. El impacto en nuestra población fue mayor que el repor tado, incluso en la población de pacientes mas graves como los lactantes con DBP...

Estrategias de prevención y tratamiento en displasia broncopulmonar / Strategies for prevention and treatment of broncopulmonary dysplasia

Bronchopulmonary Dysplasia (BPD) continues to be a highly frequent sequela of low birth weight infants. This, despite the many recent advances in perinatal medicine that include antenatal steroids, exogenous surfactant, new strategies for mechanical respiratory support, parenteral nutrition improvements and a more judicious use of supplemental oxygen. The purpose of this review is to analyze and describe the recent advances in the prevention and management of BPD. New preventive therapies have been developed, and vitamin A and caffeine administration have been shown to diminish the incidence of this disorder. Postnatal corticosteroids can also be useful, but due to their negative long-term neurological effects, these medications are not currently recommended. Corticosteroid administration in established BPD can decrease the need for mechanical ventilation and improve lung function. Other preventive interventions such as antioxidant administration and nitric oxide inhalation are currently being investigated. The persistence of the ductus arteriosus is associated with increased risk of BPD, therefore early pharmacologic closure can play a role in preventing this disorder. New modalities of mechanical ventilation, such as synchronized and high frequency ventilation, have not been shown to decrease the incidence of this disease. While a discussion regarding the best type of ventilation to be used still remains, the consensus is that that the lowest inspiratory pressure and lowest oxygen concentration necessary should be utilized to maintain adequate gas exchange. Optimal level of arterial oxygen saturation in premature infants is still controversial, but the current recommended range is between 88 percent and 95 percent. Summary: Vitamin A and caffeine are both effective drugs in the prevention of BPD. The role of early closure of the ductus arteriosus and the use of postnatal administration of corticosteroids in the prevention of BPD are...

La Displasia Broncopulmonar (DBP) es una de las secuelas más frecuentes que afecta al recién nacido de muy bajo peso. Esto es, a pesar de los avances de la medicina perinatal de los últimos años, como la administración de corticoides antenatales, surfactante exógeno, nuevos modos y estrategias de ventilación mecánica, mejoría de la nutrición parenteral y el uso más cuidadoso del oxígeno. El objetivo de la presente revisión es analizar y describir los recientes avances en la prevención y tratamiento de la DBP. Nuevas terapias preventivas han emergido, habiéndose demostrado que la administración de vitamina A y cafeína disminuyen la incidencia de esta afección. Los corticoides postnatales también disminuyen la incidencia de esta enfermedad, pero por sus efectos neurológicos a largo plazo, no se recomiendan actualmente. La administración de corticoides en la DBP establecida reduce el uso de ventilación mecánica y mejora la función pulmonar del recién nacido. Otras intervenciones preventivas como la administración de antioxidantes y óxido nítrico inhalado están siendo estudiadas. La persistencia del ductus arterioso se ha asociado a displasia, por lo cual, el cierre farmacológico precoz podría tener relevancia en la prevención de esta. Los nuevos modos de ventilación mecánica, como la ventilación sincronizada y la ventilación de alta frecuencia, no han disminuido la incidencia de esta enfermedad. Cualquiera sea el tipo de ventilación utilizada, debe aplicarse con la menor presión inspiratoria y concentración de oxígeno requeridas, para mantener un adecuado intercambio gaseoso. El rango de saturación arterial de oxígeno recomendado para el niño prematuro, aún es motivo de estudio, pero la recomendación actual más ampliamente aceptada es aquella que oscila entre 88 por ciento y 95 por ciento. Conclusión: La vitamina A y la cafeína son drogas efectivas en la prevención de la DBP. Faltan estudios para determinar con mayor exactitud el posible...

Bronchopulmonary dysplasia in very low birth weight infants.

Objective. To determine the risk factors for development of bronchopulmonary dysplasia (BPD) by evaluating mild and moderate/severe BPD in extramural neonates with a birth weight <1501 g. Methods. A case-control study was conducted between January 1, 2004- December 31, 2006. Patients with BPD and without BPD were compared. Bronchopulmonary dysplasia was diagnosed and classified according to the Bancalari criteria. One-hundred and six (106) extramural premature infants with a birth weight <1501 g and admitted to the Neonatal Unit in the first three days of life and survived for more than 28 postnatal days were included. Patients with multiple congenital anomalies and complex cardiac pathologies were excluded. The maternal and neonatal risk factors, clinical features, mechanical ventilation treatment were compared. The principal risk factors for BPD development were analyzed and followed by logistic regression test. Results. The diagnosis was mild BPD in 27 of the 106 patients and moderate/severe BPD in 29. The incidence of BPD was 52.8%. Fifty of 106 patients had no BPD. Analysis of risk factors revealed that gestational age ≤28 weeks (p=0.019), birth weight ≤1000 g (p=0.007), hypothermia (p=0.003), acidosis (p=0.003) and hypotension (p=0.005) at admission, respiratory distress syndrome (RDS) ( p<0.001), mechanical ventilation therapy (p<0.001), surfactant therapy (p=0.005), higher amount of mean fluid therapy on 7th days (p=0.008), nosocomial infection (p<0.001), higher amount of mean packed red cell transfusions (p<0.001) and more than two packed red cell transfusions (p=0.033) were risk factors associated with the development of BPD. Multivariant logistic regression analysis showed acidosis at admission (OR 5.12, 95%CI 1.17–22.27, p=0.029), surfactant treatment (OR 7.53, 95%CI 2.14–26.45, p=0.002), nosocomial infections (OR 4.66, 95%CI 1.27–17.12, p=0.02) and PDA (OR 9.60, 95%CI 2.23–41.22, p=0.002) were risk factors increasing the severity of BPD. Conclusion. The most important risk factors for BPD development in our study were RDS and nosocomial infections while the presence of acidosis at admission, surfactant administration, nosocomial infections and the presence of PDA were the most important risk factors regarding BPD severity. Presence of acidosis at admission as a risk factor emphasized the importance of suitable transport conditions for premature infants.

Displasia broncopulmonar / Bronchopulmonary dysplasia

OBJETIVO: Apresentar uma ampla revisão da literatura sobre displasia broncopulmonar, abordando novas definições, fisiopatologia, prevenção, tratamento, prognóstico e evolução. FONTE DOS DADOS: Foram selecionados os artigos mais relevantes sobre o tema, desde a sua descrição inicial, em 1967, pesquisados na MEDLINE. SíNTESE DOS DADOS: A displasia broncopulmonar é considerada uma das principais causas de doença pulmonar crônica em lactentes. Está associada a hospitalizações freqüentes e prolongadas, especialmente por doenças pulmonares, altos índices de mortalidade e alterações no desenvolvimento neuropsicomotor e no crescimento pôndero-estatural. A patogênese é complexa e influenciada principalmente por prematuridade, infecção, oxigênio suplementar e ventilação mecânica. A prevenção envolve o acompanhamento pré-natal adequado, a prevenção do parto prematuro, o uso pré-natal do corticosteróide, a terapia de reposição de surfactante e o uso de estratégias ventilatórias "protetoras". O tratamento do paciente com displasia broncopulmonar demanda uma equipe multidisciplinar. Quando indicada, a suplementação de oxigênio é de extrema importância. Apesar de maior risco de morbimortalidade nos primeiros anos de vida, a evolução em longo prazo é favorável na maioria das vezes. CONCLUSÕES: A displasia broncopulmonar vem sendo profundamente estudada na tentativa de identificação das suas causas e possibilidades de prevenção e de tratamento. Ainda existem controvérsias quanto a esses assuntos e também em relação ao prognóstico desses pacientes, especialmente quando se trata da evolução tardia da "nova" displasia broncopulmonar.

Como minimizar a lesão pulmonar no prematuro extremo: propostas / Strategies to minimize lung injury in extremely low birth weight infants

OBJETIVO: Apresentar uma revisão das principais causas da nova displasia broncopulmonar e as estratégias utilizadas para diminuir sua incidência nos prematuros extremos. FONTES DOS DADOS: Para essa revisão, pesquisas foram feitas na MEDLINE (1996 a outubro de 2004), no Cochrane Database, em resumos da Society for Pediatric Research e recentes conferências sobre o tema. SíNTESE DOS DADOS: A tecnologia e os novos conhecimentos científicos têm aumentado significantemente a sobrevida de prematuros extremos. Esse aumento da sobrevida resultou em aumento da incidência de displasia broncopulmonar. Atualmente, a displasia broncopulmonar é mais freqüentemente observada em recém-nascidos < 1.200 g. As características da displasia broncopulmonar nesses prematuros extremos, atualmente chamada de "nova" displasia broncopulmonar, são bastante diferentes da clássica descrita por Northway. A nova displasia broncopulmonar tem etiologia multifatorial, como volutrauma, atelectrauma, toxicidade ao oxigênio e reação inflamatória. Terapias como corticosteróide pré-natal, surfactante exógeno, pressão aérea positiva contínua nasal, novos tipos de ventilação mecânica e uma ventilação mais gentil têm sido usadas para tentar diminuir a gravidade da lesão pulmonar. CONCLUSÕES: Para prevenir a lesão pulmonar em prematuros extremos, é necessário minimizar os vários fatores que desencadeiam a displasia broncopulmonar e utilizar estratégias terapêuticas menos agressivas. O melhor conhecimento desses fatores de risco da displasia broncopulmonar poderá gerar novas terapêuticas, que, conjuntamente com o tratamento utilizado atualmente para minimizar a lesão pulmonar, serão fundamentais para uma melhor evolução clínica desses prematuros extremos.

Incidencia de displasia broncopulmonar en el Servicio de Neonatología del Hospital Pablo Soria, de San Salvador de Jujuy / Incidence of bronchopulmonary dysplasia in the neonatology service of the Hospital Pablo Soria, of San Salvador de Jujuy

Durante el período comprendido entre el 1 de enero de 1997 y el 31 de diciembre de 2003, ingresaron al Servicio de Neonatología del Hospital Pablo Soria 796 recién nacidos cuyo peso al nacer fue igual o menor de 1.500 gramos. La mortalidad en el servicio oscila entre el 20 y el 35 por ciento anual para los neonatos con este peso de nacimiento. Cincuenta y nueve recién nacidos (7,4 por ciento) tuvieron Displasia Broncopulmonar (DBP). Se analizaron los factores de riesgo para esta patología, características clínicas y de manejo terapéutico y el crecimiento alcanzado durante la internación. Se observó un aumento en la incidencia de la patología, una clara tendencia al manejo conservador de la misma, un mejor estado nutricional al momento del alta comparado con la población sin DBP y un aumento en el número de recién nacidos MBPN con una presentación clínica de la enfermedad distinta a la DBP clásica, menos grave con un cuadro respiratorio inicial leve que no requiere ventilación mecánica.